Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
3d
Interesting Engineering on MSNLepodisiran drug shows unprecedented 94% drop in heart disease risk factor: StudyEli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
Explore more
2d
ZME Science on MSNAn Experimental Drug Just Slashed Genetic Heart Risk by 94%On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...
Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.
Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results